Literature DB >> 29264221

Current consensus and controversies on male LUTS/BPH (part one).

Keong Tatt Foo1.   

Abstract

Entities:  

Year:  2017        PMID: 29264221      PMCID: PMC5717974          DOI: 10.1016/j.ajur.2017.06.005

Source DB:  PubMed          Journal:  Asian J Urol        ISSN: 2214-3882


× No keyword cloud information.
It is an honor to be the guest editor of this special issue on Current Consensus and Controversy on Male Lower Urinary Tract Symptoms (LUTS)/Benign Prostatic Hyperplasia (BPH). As the title implies, one can write on a wide range of topics related to this urological problem that is common worldwide. I am confident that many authors who contributed in this issue will help provide a better perspective and hopefully point the directions for future research and further improve on the care of our patients with this disorder in our aging society. This issue covers the latest evidence available in the field from epidemiology, etiology to pathophysiology as well as the latest developments in the treatment of the disease, including conservative management, medical treatment and surgical treatment encompassing minimally invasive techniques. Prof. Louis Denis, who was the Chairman of the 5th International Consultation on BPH (2001), and his colleague Prof. Johan Braeckman, kindly contributed the introductory chapter on “Management of BPH then 2000 and now 2016” [1]. This is followed by an article which discusses the epidemiology [2] and possible etiology of clinical BPH [3], including the role of inflammation [4] and association of metabolic syndrome [5] with clinical BPH. Based on fundamental principles, scientific evidence and clinical observations, the disease clinical BPH can be defined as prostate adenoma/adenomata causing a varying degree of obstruction, with or without symptoms. The diagnosis of clinical BPH can then be made using non-invasive transabdominal ultrasound to measure the intravesical prostatic protrusion (IPP) and uroflowmetry [3], [6]. The disease clinical BPH can then be differentiated from other causes of male LUTS, allowing treatment to be directed towards treating the disease rather than the symptoms. Furthermore, clinical BPH can be phenotyped according to the IPP and prostate volume for prognosis. The severity of BPH can be staged according to the degree of obstruction affecting the functions of the bladder and kidneys, and patients' quality of life [3]. Treatment ranging from lifestyle counseling [7], medical therapy [8], [9] to surgical procedures [10] can then be individualized and personalized for management of the patient as a whole [3]. This would be in line with the fundamentals of good clinical practice in real life. I would like to thank the authors who have contributed to this issue and subjected their articles to critical review. I am grateful to the reviewers for contributing their time and effort to improve the articles. In scientific writing, there is always room for improvement, even though you may be the expert in the field. I personally learned much from writing and guest editing this special issue on male LUTS/BPH. It has given me a better insight and perspective, and I hope the reader will benefit from and enjoy reading the articles as much as I have.
  10 in total

Review 1.  Epidemiology of clinical benign prostatic hyperplasia.

Authors:  Kok Bin Lim
Journal:  Asian J Urol       Date:  2017-06-09

Review 2.  Metabolic syndrome and benign prostatic hyperplasia: An update.

Authors:  Ho-Yin Ngai; Kar-Kei Steffi Yuen; Chi-Man Ng; Cheung-Hing Cheng; Sau-Kwan Peggy Chu
Journal:  Asian J Urol       Date:  2017-05-25

Review 3.  The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men.

Authors:  Kok Kit Ng; Foo Cheong Ng
Journal:  Asian J Urol       Date:  2017-05-26

Review 4.  Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination.

Authors:  Cheuk Fan Shum; Weida Lau; Chang Peng Colin Teo
Journal:  Asian J Urol       Date:  2017-06-09

Review 5.  Management of BPH then 2000 and now 2016 - From BPH to BPO.

Authors:  Johan Braeckman; Louis Denis
Journal:  Asian J Urol       Date:  2017-03-30

Review 6.  Pathophysiology of clinical benign prostatic hyperplasia.

Authors:  Keong Tatt Foo
Journal:  Asian J Urol       Date:  2017-06-13

Review 7.  Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases.

Authors:  Darab Mehraban
Journal:  Asian J Urol       Date:  2017-01-20

Review 8.  Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians.

Authors:  Farhad Fakhrudin Vasanwala; Michael Yuet Chen Wong; Henry Sun Sien Ho; Keong Tatt Foo
Journal:  Asian J Urol       Date:  2017-06-14

Review 9.  The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia.

Authors:  Rikiya Taoka; Yoshiyuki Kakehi
Journal:  Asian J Urol       Date:  2017-05-25

Review 10.  An update on transurethral surgery for benign prostatic obstruction.

Authors:  Jonathan Shunming Teo; Yee Mun Lee; Henry Sun Sien Ho
Journal:  Asian J Urol       Date:  2017-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.